New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
18:41 EDTMELI, ZNGA, POST, CPST, TKMR, LULU, MNST, SCTY, NVDA, MDVN, ANET, UBNT, LRAD, FOLD, SLXPOn The Fly: After Hours Movers
UP AFTER EARNINGS: MercadoLibre (MELI), up 14.2%... Amicus Therapeutics (FOLD), up 10.5%... LRAD Corporation (LRAD), up 18%... Ubiquiti Networks (UBNT), up 7%... Arista Networks (ANET), up 8.8%... Medivation (MDVN), up 4.2%... NVIDIA (NVDA), up 4.5%... SolarCity (SCTY), up 4.6%... Monster Beverage (MNST), up 2.5%. ALSO HIGHER: Lululemon Athletica (LULU), up 5.7% following announcement that founder Chip Wilson will sell half his stake to Advent International... Tekmira Pharmaceuticals (TKMR), up 7.2% after announcing that the FDA verbally confirmed they have modified the full clinical hold placed on the TKM-Ebola to a partial clinical hold. DOWN AFTER EARNINGS: Capstone Turbine (CPST), down 12%... Post Holdings (POST), down 13.1% after reporting quarterly results and that it acquired American Blanching for $128M in cash... Zynga (ZNGA), down 7.2% after lowering fiscal 2014 guidance... Salix Pharmaceuticals (SLXP), down 3.4%.
News For MELI;FOLD;LRAD;UBNT;ANET;MDVN;NVDA;SCTY;MNST;LULU;TKMR;CPST;POST;ZNGA;SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 9, 2014
05:50 EDTTKMRStocks with implied volatility movement; ARWR TKMR
Stocks with implied volatility movement; Arrowhead (ARWR) 158, Tekmira (TKMR) 130 according to iVolatility.
October 8, 2014
15:03 EDTFOLDUCLA researchers report positive results in mouse model of Parkinsonís
Subscribe for More Information
11:59 EDTTKMRTekmira volatility increases after Ebola patient dies
Subscribe for More Information
11:22 EDTTKMRChimerix falls after Ebola patient taking experimental drug dies
Shares of Chimerix (CMRX) are moving lower after the Texas Health Presbyterian Hospital Dallas announced that Thomas Eric Duncan succumbed to Ebola. Duncan was being treated with Chimerix's experimental drug Brincidofovir. Shares of Chimerix dropped 9% following the news to $30.19. Other makers of experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT) and BioCryst (BCRX).
10:48 EDTZNGAGlu drops despite Benchmark optimism about Kardashian game
Research firm Benchmark Co. upgraded digital video game maker Glu Mobile (GLUU) to Buy from Hold, based on optimism about the company's upcoming third quarter earnings report. WHAT'S NEW: Glu may report higher than expected third quarter sales and earnings before interest taxes depreciation and amortization on October 29, Benchmark analyst Mike Hickey wrote in a note to investors today. The company may also raise its fourth quarter guidance, Hickey believes. Glu's results are being lifted by the success of the company's "Kim Kardashian: Hollywood" game, the analyst believes. He has a $5.90 price target on the name. WHAT'S NOTABLE: Taking the opposite view on Glu Mobile in an article yesterday was a short-selling blog, TheStreetSweeper. The blog said it "wouldn't be surprised" if the company cut its Q4 guidance, as Kim Kardashian and other Glu games "are fading fast." Company insiders are "selling huge chinks" of the company's shares, added the blog. Northland Capital analyst Darren Aftahi yesterday countered by accusing TheStreetSweeper of "acting as a megaphone" for shorts in the name, trying to drive down the stock in a weak market, and producing an article that is "full of conjecture." The analyst said he thinks the company could beat Q3 revenue expectations by a large amount, potentially producing a "massive short squeeze." OTHERS TO WATCH: Other digital video game makers include Zynga (ZNGA) and King Digital (KING). PRICE ACTION: In early trading, Glu dropped 4% to $4.56.
10:01 EDTSCTYSolarCity and Honda renew partnership to fund $50M in solar projects
Subscribe for More Information
10:00 EDTANETOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:42 EDTSLXPSalix shares should be bought on weakness, says Sterne Agee
After Reuters yesterday afternoon reported that Actavis (ACT) plans to make a new merger approach to Allergan (AGN), Sterne Agee believes that Salix's standalone value is $162. The firm expects the shares to reach that level following approval of its Xifaxan IBS-D drug after the February 2015 PDUFA date.
08:31 EDTSLXPSalix announces FDA granted final approval for UCERIS
Subscribe for More Information
08:11 EDTSCTYSolarCity launch of MyPower expected but details a positive, says BofA/Merrill
Subscribe for More Information
07:10 EDTANETArista Networks initiated with a Buy at MKM Partners
Target $115.
06:23 EDTSLXPActavis more inclined to pursue Allergan over Salix, says Citigroup
Subscribe for More Information
06:02 EDTSCTYSolarCity adds financing option in move to expand
SolarCity introduced MyPower today, a solar financing option that combines the low upfront cost and immediate utility savings of a power purchase agreement with the benefits of ownership. SolarCity customers pay for their MyPower solar loan similar to the way they pay for a solar PPAóbased on the energy the system produces from the sunóbut they retain ownership of the solar panels. MyPower's unique structure creates America's most affordable solar loanówith a lower cost than PPAs in many locations. MyPower can allow customers to pay as much as 40% less for solar power than utility power, and unlike other loans, MyPower allows customers to prepay their entire balance or prepay a portion of their solar loan to lower their monthly payments at any time, with no fees or penalties. Starting today, SolarCity will offer MyPower to customers in Arizona, California, Colorado, Connecticut, Hawaii, Massachusetts, New York and New Jersey, and ultimately plans to expand the product beyond its existing service territory.
06:00 EDTLULUStocks with implied volatility below IV index mean; ADHD LULU
Stocks with implied volatility below IV index mean; Alcobra (ADHD) 123, lululemon (LULU) 35 according to iVolatility.
October 7, 2014
15:21 EDTSLXPAllergan warms to sale as Actavis plans new approach, Reuters says
Subscribe for More Information
14:52 EDTMNSTMonster Beverage sales up 17.6% for four week period, says Goldman
Goldman said Monster's energy drink sales grew 17.6% vs total energy drink sales growth of 12.9% for the same four weeks ending September 27, according to Nielsen data.
13:45 EDTTKMRTekmira at 5-session lows, levels to watch
Subscribe for More Information
13:28 EDTTKMRTekmira down 5% after report says Chimerix drug used on NBC journalist
Subscribe for More Information
07:48 EDTSLXPSalix reinstated with a Buy at Jefferies
Subscribe for More Information
07:33 EDTMDVNMedivation resumed with an Outperform at JMP Securities
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use